Executive Series: The Campbell Alliance Dealmakers’ Intentions Survey
Following a highly successful Super Session at the BIO International Convention, Campbell Alliance will share the results of its fourth annual Dealmakers’ Intentions Survey, the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.
In 2012, in-licensers are pushing risk down the food chain to out-licensers. Supply and demand is skewed heavily toward in-licensers demanding de-risked, late-stage assets in the most established therapeutic areas.
However, the number of de-risked assets is relatively lacking, making the 2012 licensing environment a scary one. Discount rates have been rising, which is driving the in-licensers to chase late-stage assets. For those who can accept a long investment horizon in the face of these pressures, a relative surplus of early-stage oncology assets may exist, representing true buying opportunities. Buying opportunities in off-the-beaten-path asset classes may also exist, especially for those in development stages. In short, safety will be expensive in 2012.
This highly interactive discussion will address these issues and others.
A comprehensive white paper summarizing the results will be distributed onsite at the event.
Senior Practice Executive, Campbell Alliance
Practice Executive, Campbell Alliance
The Campbell Alliance
Dealmakers’ Intentions Survey
Tuesday, October 16, 2012
Breakfast and Networking: 7:30AM – 8:00AM
Discussion: 8:00AM – 9:00AM
OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
|Attire:||Business attire suggested|
RSVP by October 12th is required
No on-site registrations accepted
Open to C-Suite Executives of
BayBio Members – FREE
Non-Members – $75.00